Literature DB >> 2545440

Cell type specific trans-acting factors are involved in alternative splicing of human fibronectin pre-mRNA.

M V Barone1, C Henchcliffe, F E Baralle, G Paolella.   

Abstract

ED-A and ED-B are facultative type III homologies of fibronectin, encoded by alternatively spliced exons, described in man and in rat. A hybrid alpha-globin-fibronectin minigene containing the ED-B region from the human gene has been transfected in human cell lines derived from various tissues, in order to study the processing of the generated precursor RNA in the different cell environments. In most tested lines the pre-RNA is alternatively spliced and produces two mature RNAs, with and without the ED-B exon, in different ratios that closely resemble the corresponding endogenous fibronectin RNAs. In a hepatoma cell line, Hep 3B, only one RNA is produced, in which the ED-B exon is absent; the same pattern of splicing is observed in liver. The data show that all the information required to produce accurate and regulated alternative splicing of the ED-B exon is contained in the fragment used and cell specific factors are necessary for the pre-RNA to be differentially spliced in the various cell lines. In contrast, expression in Hep 3B of a similar gene containing the ED-A area failed to reproduce the liver specific splicing pattern. Therefore regulation of ED-A processing is likely to involve different mechanisms to those responsible for control of ED-B splicing.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2545440      PMCID: PMC400917          DOI: 10.1002/j.1460-2075.1989.tb03476.x

Source DB:  PubMed          Journal:  EMBO J        ISSN: 0261-4189            Impact factor:   11.598


  28 in total

1.  Localization of the cellular-fibronectin-specific epitope recognized by the monoclonal antibody IST-9 using fusion proteins expressed in E. coli.

Authors:  B Carnemolla; L Borsi; L Zardi; R J Owens; F E Baralle
Journal:  FEBS Lett       Date:  1987-05-11       Impact factor: 4.124

2.  Cell-type-specific fibronectin subunits generated by alternative splicing.

Authors:  J I Paul; J E Schwarzbauer; J W Tamkun; R O Hynes
Journal:  J Biol Chem       Date:  1986-09-15       Impact factor: 5.157

3.  Splicing of messenger RNA precursors.

Authors:  P A Sharp
Journal:  Science       Date:  1987-02-13       Impact factor: 47.728

4.  Role of an RNA cleavage/poly(A) addition site in the production of membrane-bound and secreted IgM mRNA.

Authors:  D Danner; P Leder
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

Review 5.  Pre-mRNA splicing.

Authors:  M R Green
Journal:  Annu Rev Genet       Date:  1986       Impact factor: 16.830

Review 6.  Molecular biology of fibronectin.

Authors:  R Hynes
Journal:  Annu Rev Cell Biol       Date:  1985

7.  Developmentally induced, muscle-specific trans factors control the differential splicing of alternative and constitutive troponin T exons.

Authors:  R E Breitbart; B Nadal-Ginard
Journal:  Cell       Date:  1987-06-19       Impact factor: 41.582

8.  Splice commitment dictates neuron-specific alternative RNA processing in calcitonin/CGRP gene expression.

Authors:  S E Leff; R M Evans; M G Rosenfeld
Journal:  Cell       Date:  1987-02-13       Impact factor: 41.582

9.  Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon.

Authors:  L Zardi; B Carnemolla; A Siri; T E Petersen; G Paolella; G Sebastio; F E Baralle
Journal:  EMBO J       Date:  1987-08       Impact factor: 11.598

10.  Monoclonal antibodies in the analysis of fibronectin isoforms generated by alternative splicing of mRNA precursors in normal and transformed human cells.

Authors:  L Borsi; B Carnemolla; P Castellani; C Rosellini; D Vecchio; G Allemanni; S E Chang; J Taylor-Papadimitriou; H Pande; L Zardi
Journal:  J Cell Biol       Date:  1987-03       Impact factor: 10.539

View more
  20 in total

1.  Sequences regulating temporal poly(A) site switching in the adenovirus major late transcription unit.

Authors:  J D DeZazzo; E Falck-Pedersen; M J Imperiale
Journal:  Mol Cell Biol       Date:  1991-12       Impact factor: 4.272

2.  Exon as well as intron sequences are cis-regulating elements for the mutually exclusive alternative splicing of the beta tropomyosin gene.

Authors:  D Libri; M Goux-Pelletan; E Brody; M Y Fiszman
Journal:  Mol Cell Biol       Date:  1990-10       Impact factor: 4.272

3.  In vitro splicing of fibronectin pre-mRNAs.

Authors:  P A Norton; R O Hynes
Journal:  Nucleic Acids Res       Date:  1990-07-25       Impact factor: 16.971

4.  Alternative splicing of the fibronectin EIIIB exon depends on specific TGCATG repeats.

Authors:  L P Lim; P A Sharp
Journal:  Mol Cell Biol       Date:  1998-07       Impact factor: 4.272

5.  A subfragment of the beta tropomyosin gene is alternatively spliced when transfected into differentiating muscle cells.

Authors:  D Libri; J Marie; E Brody; M Y Fiszman
Journal:  Nucleic Acids Res       Date:  1989-08-25       Impact factor: 16.971

6.  Cell-type-specific expression of alternatively spliced human fibronectin IIICS mRNAs.

Authors:  R P Hershberger; L A Culp
Journal:  Mol Cell Biol       Date:  1990-02       Impact factor: 4.272

Review 7.  Pathophysiological aspects of VLA-4 interactions and possibilities for therapeutical interventions.

Authors:  T W Kuijpers
Journal:  Springer Semin Immunopathol       Date:  1995

8.  Id proteins control growth induction in mammalian cells.

Authors:  M V Barone; R Pepperkok; F A Peverali; L Philipson
Journal:  Proc Natl Acad Sci U S A       Date:  1994-05-24       Impact factor: 11.205

9.  Differential ASF/SF2 activity in extracts from normal WI38 and transformed WI38VA13 cells.

Authors:  B Chabot; D Frappier; H La Branche
Journal:  Nucleic Acids Res       Date:  1992-10-11       Impact factor: 16.971

Review 10.  New insights into form and function of fibronectin splice variants.

Authors:  E S White; F E Baralle; A F Muro
Journal:  J Pathol       Date:  2008-09       Impact factor: 7.996

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.